Logo

Abbott's AdviseDx SARS-CoV-2 IgM Test Receives the US FDA's EUA for COVID-19

Share this

Abbott's AdviseDx SARS-CoV-2 IgM Test Receives the US FDA's EUA for COVID-19

Shots:

  • Abbott has received the US FDA’s EUA for AdviseDx SARS-CoV-2 IgM lab-based serology test for use on the ARCHITECT and Alinity platforms
  • Till now- Abbott has received EUA for its seven tests- including molecular tests- a rapid antigen test and- an IgG Ab test for COVID-19
  • The IgM test demonstrated 99.56% specificity and 95.00% sensitivity for patients tested 15 days after symptom onset. The test will give a more complete picture of where patients are in their recovery

     ­ Ref: Abbott | Image: Abbott
Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions